These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30815829)

  • 1. A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.
    Melzer-Cohen C; Chodick G; Husemoen LLN; Rhee N; Shalev V; Karasik A
    Diabetes Ther; 2019 Apr; 10(2):683-696. PubMed ID: 30815829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.
    Lind M; Matsson PO; Linder R; Svenningsson I; Jørgensen L; Ploug UJ; Gydesen H; Dorkhan M; Larsen S; Johansson G
    Diabetes Ther; 2016 Jun; 7(2):321-33. PubMed ID: 27216947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.
    Hadjiyianni I; Desai U; Suzuki S; Ivanova JI; Cao D; Kirson NY; Chida D; Enloe C; Birnbaum HG; Perez-Nieves M
    Diabetes Ther; 2017 Feb; 8(1):149-166. PubMed ID: 27913984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
    Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
    Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.
    Melzer-Cohen C; Chodick G; Naftelberg S; Shehadeh N; Karasik A
    Diabetes Ther; 2020 Jan; 11(1):185-196. PubMed ID: 31808132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
    Inoue K; Maeda N; Fujishima Y; Fukuda S; Nagao H; Yamaoka M; Hirata A; Nishizawa H; Funahashi T; Shimomura I
    Diabetol Metab Syndr; 2014; 6(1):95. PubMed ID: 25237400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
    Ostawal A; Mocevic E; Kragh N; Xu W
    Diabetes Ther; 2016 Sep; 7(3):411-38. PubMed ID: 27350545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.
    Perez-Nieves M; Ivanova JI; Hadjiyianni I; Zhao C; Cao D; Schmerold L; Kalirai S; King S; DeLozier AM; Birnbaum HG; Peyrot M
    Curr Med Res Opin; 2017 Oct; 33(10):1833-1842. PubMed ID: 28604111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.
    Lundershausen R; Müller S; Hashim M; Kienhöfer J; Kipper S; Wilke T
    Exp Clin Endocrinol Diabetes; 2020 Mar; 128(3):170-181. PubMed ID: 30157532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.
    Dang-Tan T; Kamble PS; Meah Y; Gamble C; Ganguly R; Horter L
    Diabetes Ther; 2020 Jan; 11(1):213-228. PubMed ID: 31820328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany.
    Moennig E; Perez-Nieves M; Hadjiyianni I; Cao D; Ivanova J; Klask R
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):287-297. PubMed ID: 28895642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.
    Mezquita-Raya P; Reyes-Garcia R; Moreno-Perez O; Escalada-San Martin J; Ángel Rubio Herrera M; Lopez de la Torre Casares M
    Diabetes Ther; 2015 Jun; 6(2):173-85. PubMed ID: 26055216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.